Issue 3, 2012

Chiral diaminocyclohexane coupling polyphenols: A new class of anticancer agents

Abstract

A new class of chiral diamine coupled polyphenols, compounds 38 were synthesized and tested against breast cancer (MCF-7), lung cancer (HBT-174, NCI-H460) and metastatic cancer cell lines (MDA-MB-453, MDA-MB-231 and MDA-MB-468). The results, based on SRB assay and colony formation assay, indicate that the compounds are selectively cytotoxic towards cancer cell-lines, and particularly towards metastatic cancer cell-lines. Gene expression studies by Real time RT-PCR demonstrated that compound 5 is an efficient regulator of antiapoptotic genes (Bcl-2) and cell cycle (cyclin D1) related genes. Moreover, compound 5 was evaluated using an isolated ALDH1-positive cell sub-population of metastatic MDA-MB-453 cells. In vitro mammosphere formation assay shows that this compound is highly inhibitory towards mammosphere formation and cell proliferation. These results indicate that the compounds investigated represent a class of effective and selectively toxic anticancer agents.

Graphical abstract: Chiral diaminocyclohexane coupling polyphenols: A new class of anticancer agents

Article information

Article type
Concise Article
Submitted
30 Sep 2011
Accepted
13 Nov 2011
First published
23 Nov 2011

Med. Chem. Commun., 2012,3, 326-332

Chiral diaminocyclohexane coupling polyphenols: A new class of anticancer agents

J. Gao and R. A. Zingaro, Med. Chem. Commun., 2012, 3, 326 DOI: 10.1039/C2MD00248E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements